Physician profile
Stephen Winkler
NPI 1104158591
$2,882.23
in general payments reported to CMS, 2019-2025
17 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.95 · 2020: $35.70 · 2021: $199 · 2022: $595 · 2023: $790 · 2024: $598 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,052.80 | 2022-2025 | Xen Glaucoma Treatment System, Lumigan, Vuity |
| Horizon Therapeutics Plc | $624.85 | 2020-2023 | Tepezza |
| Amgen INC. | $295.19 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $230.50 | 2025 | |
| Genentech USA, INC. | $131.75 | 2022 | |
| Mallinckrodt Hospital Products INC. | $118.95 | 2024 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $107.01 | 2022 | |
| Alcon Vision LLC | $91.15 | 2021-2025 | Eysuvis |
| Thea Pharma INC. | $65.21 | 2022-2025 | Iyuzeh |
| Organogenesis INC. | $26.49 | 2021 | |
| Bausch & Lomb Americas INC. | $25.00 | 2023 | Alrex, Zylet, Lotemax Sm |
| Ani Pharmaceuticals, INC. | $24.90 | 2022 | |
| Alimera Sciences, INC. | $21.95 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.22 | 2021 | |
| Aerie Pharmaceuticals, INC. | $16.86 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.29 | 2020 | |
| Boston Scientific Corporation | $15.11 | 2023 | Advantage System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Winkler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.